Australian cancer researchers are the first to create a next -generation gene treatment tool for modeling and interrogation of human disease.
A new preclinical model expressing a reinforced version of a new mechanical genome enzyme called CAS12A was created by researchers at Olivia Newton-John Cancer Research Institute (OnjCri), Wehi and Genentech, a member of the Roche Group.
CAS enzymes are required to reduce specific DNA or RNA parts during CRISPR experiments. CRISPR is a revolutionary gene processing tool widely used for cancer research, which is currently in the early stages of clinical application in patients.
The researchers were also able to identify genes that led to accelerated lymphoma in the preclinical model using unique CRISPR libraries that reconcile with CAS12A.
This new study contributes to a better understanding of the restrictions of CRISPR technology, with the ultimate goal of making a viable choice for cancer treatment in patients.
In the last decade, the most widely used CAS9 enzyme, Cas9, has led to many important discoveries in medical research.
Postdoctoral Researcher on Onjcri and Wehi Dr. Eddie La Marca, who is the author of the co -owner in the document published in Nature communications Today, he said:
“This is the first time Cas12A has been used in preclinical models, which will largely promote mechanical genome capabilities. Unlike CAS9, CAS12A can simultaneously delete multiple genes with extremely high efficiency.”
The researchers also used CAS12A in combination with other mechanical genome tools, allowing “multiplex” gene handling. Collaborating writers Ms. Wei Jin and Dr Yexuan Deng (Onjcr and Wehi) were edited about it:
“We have also crossed the Cas12A animal model with a model expressing a changing version of CAS9, allowing us to erase and activate different genes at the same time.
Professor Marco Herold, Managing Director of OnjCri and head of the La Trobe University Cancer Medical School, said:
“We are confident that this project will encourage other research teams to use this pre-clinical CAS12A model which, in combination with sorting libraries, is a strong new range of gene processing tools to improve mechanisms behind many different Cancer. ”
Professor Herold’s team in OnjCri also focuses on developing methods for managing CRISPR -based treatments in patients, highlighting the increasing importance of gene processing tools such as Cas12A.
Professor Herold said: “This pre-clinical Cas12A model will also help promote understanding how CRISPR tools could be translated into clinical use.”
This research was made possible by generous funding by the National Council of Health and Medical Research (NHMRC) and seemingly Australia.
Source:
Magazine report:
Jin, W., et al. (2025). Promoting the Genetic Engineering toolbar by combining ASCAS12A Knock-in mice with extremely compact control. Nature communications. Doi.org/10.1038/S41467-025-56282-2.
